Coeptis Therapeutics Holdings Inc (COEP)
NCM · Healthcare · Biotechnology
Closing price as of 2026-04-24 · Source: TEK2day Finance
Key Metrics
About Coeptis Therapeutics Holdings Inc
As of April 24, 2026, Coeptis Therapeutics Holdings, Inc. was acquired by Z Squared Inc., in a reverse merger transaction. Coeptis Therapeutics Holdings, Inc., together with its subsidiaries, operates as a biopharmaceutical and technology company. The company is developing cell therapy platforms for cancer, autoimmune, and infectious diseases. Its therapeutic portfolio includes an allogeneic cellular immunotherapy platform; and DVX201, a clinical-stage, unmodified natural killer cell therapy technology. The company's product pipeline consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; CD38-Diagnostic, an in vitro screening tool to analyze cancer patients if cancer patients might be appropriate candidates for anti-CD38 mAb therapy; and SNAP-CAR, a chimeric antigen receptor (CAR) therapy for treatment for cancer. In addition, the company offers its drugs for acute myeloid leukemia and acute respiratory diseases. Coeptis Therapeutics Holdings, Inc. has co-development agreement Vici Health Sciences, LLC to co-develop and share ownership rights to CPT60621 for the treatment of Parkinson's Disease. The company was founded in 2017 and is headquartered in Wexford, Pennsylvania.
Quarterly Financials
| Metric | 2025-03-31 | 2025-06-30 | 2025-09-30 | 2025-12-31 |
|---|---|---|---|---|
| Revenue | 63K | 201K | 237K | 862K |
| Gross Profit | 18K | 156K | 192K | 817K |
| Operating Income | -4.1M | -4.5M | -2.5M | -2.0M |
| Net Income | -3.1M | -3.5M | -2.7M | -1.6M |
| Diluted EPS | $-1.11 | $-0.95 | $-0.58 | $nan |
Annual Financials
| Metric | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 1.4M |
| Gross Profit | 0.00 | 0.00 | 0.00 | 1.2M |
| Operating Income | -34.2M | -21.5M | -10.1M | -13.0M |
| Net Income | -37.6M | -21.3M | -10.7M | -11.9M |
| Diluted EPS | $-52.60 | $-16.56 | $-5.56 | $nan |